分级分组2前列腺癌主动监测的转移风险:单中心经验
该研究回顾性分析了2000至2017年在纪念斯隆凯特琳癌症中心接受主动监测的219例分级分组2前列腺癌患者,中位随访3.1年,无患者发生远处转移或死于前列腺癌,5年无治疗生存率为61%,10年为49%,提示短期主动监测对精选患者是安全的。
要点
- 分级分组2前列腺癌主动监测短期安全,无远处转移
- 5年无治疗生存率61%,10年49%
- 需谨慎选择并密切监测患者
核心结论
- 对于精心选择并密切监测的分级分组2前列腺癌患者,主动监测在短期内似乎是安全的初始管理策略。
研究设计与样本
- 回顾性队列研究,纳入2000至2017年在纪念斯隆凯特琳癌症中心接受主动监测的219例分级分组2前列腺癌患者。
主要发现
- 中位年龄67岁(IQR 61-72),中位PSA 5 ng/ml(IQR 4-7),69%患者为非可触及病变。
- 随访期间64例接受治疗,其中根治性前列腺切除术36例(56%),放疗20例(31%),激素治疗3例(5%),局灶治疗5例(8%)。
- 36例根治性前列腺切除术后,32例(89%)病理为分级分组2,4例(11%)为分级分组3。
- 5年无治疗生存率61%(95% CI 52-70),10年49%(95% CI 37-60)。
- 3例出现生化复发,无远处转移,无前列腺癌死亡;中位随访3.1年(IQR 1.9-4.9)。
临床怎么用
- 对于经严格选择的分级分组2前列腺癌患者,可考虑主动监测作为初始管理选项,但需密切随访。
局限性
- 中位随访仅3.1年,结论需更长期随访验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We studied the risk of metastatic prostate cancer development in men with Grade Group 2 disease managed with active surveillance at Memorial Sloan Kettering Cancer Center. MATERIALS AND METHODS: A total of 219 men with Grade Group 2 prostate cancer had disease managed with active surveillance between 2000 and 2017. Biopsy was performed every 2 to 3 years, or upon changes in magnetic resonance imaging, prostate specific antigen level or digital rectal examination. The primary outcome was development of distant metastasis. The Kaplan-Meier method was used to estimate treatment-free survival. RESULTS: Median age at diagnosis was 67 years (IQR 61-72), median prostate specific antigen was 5 ng/ml (IQR 4-7) and most patients (69%) had nonpalpable disease. During followup 64 men received treatment, including radical prostatectomy in 36 (56%), radiotherapy in 20 (31%), hormone therapy in 3 (5%) and focal therapy in 5 (8%). Of the 36 patients who underwent radical prostatectomy 32 (89%) had Grade Group 2 disease on pathology and 4 (11%) had Grade Group 3 disease. Treatment-free survival was 61% (95% CI 52-70) at 5 years and 49% (95% CI 37-60) at 10 years. Three men experienced biochemical recurrence, no men had distant metastasis and no men died of prostate cancer during the followup. Median followup was 3.1 years (IQR 1.9-4.9). CONCLUSIONS: Active surveillance appears to be a safe initial management strategy in the short term for carefully selected and closely monitored men with Grade Group 2 prostate cancer treated at a tertiary cancer center. Definitive conclusions await further followup.
引用
- Carlsson S, Benfante N, Alvim R, et al. Risk of Metastasis in Men with Grade Group 2 Prostate Cancer Managed with Active Surveillance at a Tertiary Cancer Center. J Urol. 2020. PMID: 31909690. doi:10.1097/JU.0000000000000742
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。